Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...

Number of Hedge Fund Holders: 106 Cramer noted that Eli Lilly and Company (NYSE:LLY) is being careful with its promotion and predicted that the company will be back to its full strength soon enough.

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

Novo Nordisk shares fell sharply on Friday as disappointing results from tests of its latest obesity drug wiped about €90 billion off the valuation of Europe’s largest company by market ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Novo Nordisk’s shares fell sharply on Friday as disappointing results from tests of its latest obesity ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

A little over two years ago, a whisper of a new drug was abundant. Ozempic was quickly deemed a “miracle” medication, though few could predict how quickly and vastly it would revolutionise the ...

The weight loss and diabetes drugs Wegovy and Ozempic have transformed the fortunes of Novo Nordisk, leading it to more than triple in value in the past five years. Barclays had previously modelled ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is in hot pursuit.

Osteoporosis is a disabling skeletal disorder that is characterized by decreased bone strength, predisposing patients to increased risk of bone fracture. Peak bone mass (maximum bone strength and ...